An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity

Manuel L. Penichet, Eric T. Harvill, Sherie L. Morrison

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Antibody (Ab)-based tumor therapeutics use the tumor-binding specificity of the Ab to target Fc functions or associated molecules to the site of the tumor. We have used an Ab-interleukin-2 (IL-2) fusion protein to deliver IL- 2 to a murine B cell lymphoma (38C13). This anti-Id IgG3-C(H)3-IL-2, which recognizes the idiotype present on the surface of the lymphoma has a half- life in mice approximately 17-fold longer than the half-life reported for IL- 2. Gamma camera studies showed that anti-Id IgG3-C(H)3-IL-2 localizes at the site of a subcutaneous tumor in mice. The anti-Id IgG3-C(H)3-IL-2 also shows enhanced antitumor activity compared with the combination of Ab and IL-2 administered together. However, the mechanism of antitumor activity appears to depend on the dose and the treatment schedule used. A single dose of fusion protein prevented tumor in only 50% of the animals, although all the survivors showed some evidence of immunologic memory. Although multiple doses are more effective in preventing tumor growth (87% survivors), they are ineffective in generating protective immunologic memory. Our results suggest that Ab-IL-2 fusion proteins will be useful in the diagnosis and treatment of human B cell lymphomas and other related malignancies.

Original languageEnglish (US)
Pages (from-to)597-607
Number of pages11
JournalJournal of Interferon and Cytokine Research
Volume18
Issue number8
DOIs
StatePublished - Aug 1998

Fingerprint

B-Cell Lymphoma
Interleukin-2
Immunoglobulin G
Neoplasms
Proteins
Immunologic Memory
Half-Life
Antibodies
Neoplasm Antibodies
Gamma Cameras
Antibody Specificity
Therapeutic Uses
Lymphoma
Appointments and Schedules
Growth

All Science Journal Classification (ASJC) codes

  • Immunology
  • Cell Biology
  • Virology

Cite this

@article{7b45b24de33444489ca88564439d7e2c,
title = "An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity",
abstract = "Antibody (Ab)-based tumor therapeutics use the tumor-binding specificity of the Ab to target Fc functions or associated molecules to the site of the tumor. We have used an Ab-interleukin-2 (IL-2) fusion protein to deliver IL- 2 to a murine B cell lymphoma (38C13). This anti-Id IgG3-C(H)3-IL-2, which recognizes the idiotype present on the surface of the lymphoma has a half- life in mice approximately 17-fold longer than the half-life reported for IL- 2. Gamma camera studies showed that anti-Id IgG3-C(H)3-IL-2 localizes at the site of a subcutaneous tumor in mice. The anti-Id IgG3-C(H)3-IL-2 also shows enhanced antitumor activity compared with the combination of Ab and IL-2 administered together. However, the mechanism of antitumor activity appears to depend on the dose and the treatment schedule used. A single dose of fusion protein prevented tumor in only 50{\%} of the animals, although all the survivors showed some evidence of immunologic memory. Although multiple doses are more effective in preventing tumor growth (87{\%} survivors), they are ineffective in generating protective immunologic memory. Our results suggest that Ab-IL-2 fusion proteins will be useful in the diagnosis and treatment of human B cell lymphomas and other related malignancies.",
author = "Penichet, {Manuel L.} and Harvill, {Eric T.} and Morrison, {Sherie L.}",
year = "1998",
month = "8",
doi = "10.1089/jir.1998.18.597",
language = "English (US)",
volume = "18",
pages = "597--607",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity. / Penichet, Manuel L.; Harvill, Eric T.; Morrison, Sherie L.

In: Journal of Interferon and Cytokine Research, Vol. 18, No. 8, 08.1998, p. 597-607.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity

AU - Penichet, Manuel L.

AU - Harvill, Eric T.

AU - Morrison, Sherie L.

PY - 1998/8

Y1 - 1998/8

N2 - Antibody (Ab)-based tumor therapeutics use the tumor-binding specificity of the Ab to target Fc functions or associated molecules to the site of the tumor. We have used an Ab-interleukin-2 (IL-2) fusion protein to deliver IL- 2 to a murine B cell lymphoma (38C13). This anti-Id IgG3-C(H)3-IL-2, which recognizes the idiotype present on the surface of the lymphoma has a half- life in mice approximately 17-fold longer than the half-life reported for IL- 2. Gamma camera studies showed that anti-Id IgG3-C(H)3-IL-2 localizes at the site of a subcutaneous tumor in mice. The anti-Id IgG3-C(H)3-IL-2 also shows enhanced antitumor activity compared with the combination of Ab and IL-2 administered together. However, the mechanism of antitumor activity appears to depend on the dose and the treatment schedule used. A single dose of fusion protein prevented tumor in only 50% of the animals, although all the survivors showed some evidence of immunologic memory. Although multiple doses are more effective in preventing tumor growth (87% survivors), they are ineffective in generating protective immunologic memory. Our results suggest that Ab-IL-2 fusion proteins will be useful in the diagnosis and treatment of human B cell lymphomas and other related malignancies.

AB - Antibody (Ab)-based tumor therapeutics use the tumor-binding specificity of the Ab to target Fc functions or associated molecules to the site of the tumor. We have used an Ab-interleukin-2 (IL-2) fusion protein to deliver IL- 2 to a murine B cell lymphoma (38C13). This anti-Id IgG3-C(H)3-IL-2, which recognizes the idiotype present on the surface of the lymphoma has a half- life in mice approximately 17-fold longer than the half-life reported for IL- 2. Gamma camera studies showed that anti-Id IgG3-C(H)3-IL-2 localizes at the site of a subcutaneous tumor in mice. The anti-Id IgG3-C(H)3-IL-2 also shows enhanced antitumor activity compared with the combination of Ab and IL-2 administered together. However, the mechanism of antitumor activity appears to depend on the dose and the treatment schedule used. A single dose of fusion protein prevented tumor in only 50% of the animals, although all the survivors showed some evidence of immunologic memory. Although multiple doses are more effective in preventing tumor growth (87% survivors), they are ineffective in generating protective immunologic memory. Our results suggest that Ab-IL-2 fusion proteins will be useful in the diagnosis and treatment of human B cell lymphomas and other related malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0031870775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031870775&partnerID=8YFLogxK

U2 - 10.1089/jir.1998.18.597

DO - 10.1089/jir.1998.18.597

M3 - Article

C2 - 9726441

AN - SCOPUS:0031870775

VL - 18

SP - 597

EP - 607

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 8

ER -